Analysis of methylated nucleic acid
OwnerDirk Schuebeler, Michael Philippe Weberinventors
Life of this patent
Estimating the term…
Abstract
The present invention provides a method for analysis methylation patterns in DNA and identifying aberrantly methylated genes in disease tissue. The invention also provides a method of identifying novel targets for therapeutic intervention and disease markers. Novel cancer targets are provided.
Claims27
A method for enriching methylated nucleic acid fragments in a sample of nucleic acid fragments comprising the steps of:
- (a) contacting the sample of nucleic acid fragments with an antibody specific to a methylated nucleoside under conditions suitable for binding of the antibody to the methylated nucleoside;
- (b) selecting nucleic acid fragments bound to the antibody specific to a methylated nucleoside.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A method of treatment of cancer comprising modulating the activity or expression of one of more of KIAA0789, FOXF1, ADAM12, MGC48625, SHH, PAX6, FLJ25439, TAZ, GATA3, TGFb2, ZNF566, ALX4, LOC283514 and DAP.
Use of one any one of KIAA0789, FOXF1, ADAM12, MGC48625, SHH, PAX6, FLJ25439, TAZ, GATA3, TGFb2, ZNF566, ALX4, LOC283514 and DAP in an assay to identify modulators thereof for the treatment of cancer.
A method for determining whether a human tissue is predisposed to a neo-plastic transformations comprising determining whether in a cell from the tissue a nucleic acid molecule selected from the group consisting of KIAA0789, FOXF1, ADAM12, MGC48625, SHH, PAX6, FLJ25439, TAZ, GATA3, TGFb2, ZNF566, ALX4, LOC283514 and DAP is absent, present in a mutant form or down-regulated through epigenetic mechanisms.
A method of treating or inhibiting cancer in a patient in need of such treatment comprising the steps of administering to said patient a vector capable of expressing a gene selected from the group consisting of KIAA0789—accession no. XM—033133—, FOXF1, ADAM12, MGC48625, SHH, PAX6, FLJ25439—accession no. NM—144725—, TAZ, GATA3, TGFb2, ZNF566—accession no. NM—032838—, ALX4—accession no. NM—021926—, LOC283514 and DAP.
A pharmaceutical composition comprising any one or more of the genes selected from the group consisting of KIAA0789, FOXF1, ADAM12, MGC48625, SHH, PAX6, FLJ25439, TAZ, GATA3, TGFb2, ZNF566, ALX4, LOC283514 and DAP active fragments thereof, their expression products and antibodies to their expression products, and an inert carrier.
Dependencies are inferred from the claim text.